Caladrius Biosciences (CLBS) Reports Enrollment of 70th Subject in Phase 2 T-Rex Clinical Trial of CLBS03 for Type 1 Diabetes; Triggers $2.4M Milestone Payment
Tweet Send to a Friend
Caladrius Biosciences, Inc. (NASDAQ: CLBS) announces that the 70th subject has recently been enrolled in The Sanford Project: T-Rex Study ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
